Gupta A K, Lynde C W, Lauzon G J, Mehlmauer M A, Braddock S W, Miller C A, Del Rosso J Q, Shear N H
Department of Medicine, Sunnybrook Health Science Center, Toronto, Canada.
Br J Dermatol. 1998 Mar;138(3):529-32. doi: 10.1046/j.1365-2133.1998.02140.x.
Terbinafine is an allylamine antifungal agent widely used to treat dermatophyte onychomycosis and dermatomycoses. We report 10 severe cutaneous adverse reactions associated with terbinafine therapy which required discontinuation of the antifungal agent: erythema multiforme (five patients), erythroderma (one), severe urticaria (one), pityriasis rosea (one) and worsening of pre-existing psoriasis (two patients). The spectrum of cutaneous adverse effects associated with terbinafine therapy is reviewed. Patients should be counselled about discontinuing terbinafine at the onset of a cutaneous eruption and about seeking medical advice about further management.
特比萘芬是一种烯丙胺类抗真菌药物，广泛用于治疗皮肤癣菌性甲真菌病和皮肤真菌病。我们报告了10例与特比萘芬治疗相关的严重皮肤不良反应，这些反应需要停用抗真菌药物：多形红斑（5例患者）、红皮病（1例）、严重荨麻疹（1例）、玫瑰糠疹（1例）以及原有银屑病加重（2例患者）。本文对与特比萘芬治疗相关的皮肤不良反应谱进行了综述。应告知患者在出现皮肤疹时停用特比萘芬，并就进一步的处理寻求医疗建议。
